Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REPORT
July 3, 2006
- Korosho Has Budget to Conduct Market Price Survey This Year: HIB Official
July 3, 2006
- TOPICS 2 articles
July 3, 2006
- Ryukaikon Resumes Discussions
July 3, 2006
- Concern Expressed about Qualifications of New "Registered Drug Sellers"
July 3, 2006
- LDP Starts Discussions on Further
June 26, 2006
- Taisho, Abbott Japan: Clarith/Klaricid Dry Syrup for Children
June 26, 2006
- Drug Firms' Stock Prices Plummet on News of Another Price Cut
June 26, 2006
- American Society of Clinical Oncology (ASCO) 2006: 2
June 26, 2006
- SEMINAR
June 26, 2006
- Astellas, Pfizer Make Strongest
June 26, 2006
- Teijin Aims for Sales of \120 Bil.
June 26, 2006
- PMDA Places Top Priority on
June 26, 2006
- Takeda Ties-Up with Cephalon
June 26, 2006
- JPMA
June 26, 2006
- Mediceo Paltac to Acquire
June 26, 2006
- NEW PRODUCTS
June 26, 2006
- Lilly Initiates PIII Study
June 26, 2006
- Amended PAL Will Create New Business
June 26, 2006
- HMW Fucoidan Inhibits
June 26, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…